| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The most common way to provide vascular access for hemodialysis in patients is to either create a native arteriovenous (AV) fistula or to graft an artificial vessel made by polytetrafluoroethylene (PTFE) between a native artery and vein in a clinical setting. However, the creation of a native AV fistula is often restricted due to the lack of suitable vascular sites in patients with end-stage renal disease. Thus, the AV graft currently accounts for the majority of vascular access routes in hemodialysis patients. Unfortunately, in most cases, patency of the AV graft as vascular access route is often less than 2 years. Therefore, not only the economic costs for this type of treatment, but also the need for surgical revision to correct the poor patency rate in hemodialysis patients has become a very big problem.
In this report, we will introduce our attempts for the treatment of vascular access failure in the dog AV graft models by using pharmacological and physical fashions.
|
